ILC2: There's a New Cell in Town.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. A bibliometric analysis from 2014 to 2024 reveals research hotspots and trends in the immunotherapy for glomerulonephritis.Human vaccines & immunotherapeutics · 2024
   Article
2. Lymphocytes: Versatile Participants in Acute Kidney Injury and Progression to Chronic Kidney Disease.Frontiers in physiology · 2021
   Review
3. The Pathogenic Roles of IL-22 in Colitis: Its Transcription Regulation by Musculin in T Helper Subsets and Innate Lymphoid Cells.Frontiers in immunology · 2021
   Article
4. Mesenchymal PGDLeukemia · 2020
   Article
5. Regulatory T cells in acute and chronic kidney diseases.American journal of physiology. Renal physiology · 2018
   Review

Corrections and comments

• Comment on
  IL-33-Mediated Expansion of Type 2 Innate Lymphoid Cells Protects from Progressive Glomerulosclerosis.2017

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as